Front. Mol. Biosci.
Frontiers in Molecular Biosciences
Front. Mol. Biosci.
2296-889X
Frontiers Media S.A.
10.3389/fmolb.2016.00075
Molecular Biosciences
Correction
Corrigendum: Designer Leptin Receptor Antagonist Allo-aca Inhibits VEGF Effects in Ophthalmic Neoangiogenesis Models
Coroniti Roberta
1
Farjo Rafal
2
Nuno Didier J.
2
Otvos Laszlo
3
Scolaro Laura
1
Surmacz Eva
1
*
1Sbarro Institute for Cancer Research and Molecular Medicine, Temple University Philadelphia, PA, USA
2Department of Biology, Temple University Philadelphia, PA, USA
3EyeCRO Oklahoma, OK, USA
Edited and reviewed by: Ali Tavassoli, University of Southampton, UK
*Correspondence: Eva Surmacz surmacz@temple.edu
This article was submitted to Chemical Biology, a section of the journal Frontiers in Molecular Biosciences
18
11
2016
2016
3
75
26
10
2016
31
10
2016
Copyright © 2016 Coroniti, Farjo, Nuno, Otvos, Scolaro and Surmacz.
2016
Coroniti, Farjo, Nuno, Otvos, Scolaro and Surmacz
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
A corrigendum on Designer Leptin Receptor Antagonist Allo-aca Inhibits VEGF Effects in Ophthalmic Neoangiogenesis Models by Coroniti, R., Farjo, R., Nuno, D. J., Otvos, L., Scolaro, L., and Surmacz, E. (2016). Front. Mol. Biosci. 3:67. doi: 10.3389/fmolb.2016.00067
leptin
ObR antagonist
peptide drug
VEGF
ocular neoangiogenesis
In the original article, the name of the author Rafal Farjo was misspelled as Rafal Fario.
The correct spelling appears above. The authors apologize for this error. This does not change the scientific conclusions of the article in any way.
The original article has been updated.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.